HPQ
63
6
WU
32
2
CMA
61
5
HOG
35
2
HP
48
3
ROST
63
12
WY
54
4
PPL
54
-5
KHC
24
13
CMG
72
5
UA
50
-9
JPM
69
2
SIG
52
3
CTSH
56
2
WEC
53
-2
HRB
57
5
WAT
55
2
HD
57
2
MSFT
50
3
NWS
66
-3
HPQ
63
6
WU
32
2
CMA
61
5
HOG
35
2
HP
48
3
ROST
63
12
WY
54
4
PPL
54
-5
KHC
24
13
CMG
72
5
UA
50
-9
JPM
69
2
SIG
52
3
CTSH
56
2
WEC
53
-2
HRB
57
5
WAT
55
2
HD
57
2
MSFT
50
3
NWS
66
-3
Financhill
Back

ProPhase Labs 10K Form

Sell
18

PRPH
ProPhase Labs

Last Price:
0.77
Seasonality Move:
13.45%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PRPH News And Ratings

See the #1 stock for the next 7 days that we like better than PRPH

PRPH Financial Statistics

Sales & Book Value

Annual Sales: $44.38M
Cash Flow: $-4.21M
Price / Cash Flow: 0
Annual Sales: $2.00
Price / Book: 0.48

Profitability

EPS (TTM): -1.54000
Net Income (TTM): $-27.76M
Gross Margin: $16.24M
Return on Equity: -59.59%
Return on Assets: -30.23%

ProPhase Labs Earnings Forecast

Key ProPhase Labs Financial Ratios

  • The Gross Profit Margin over the past 27 years for PRPH is 36.59%.
  • The Selling, General & Administrative Expenses for PRPH have been equal to 77.74% of Gross Profit Margin.
  • The Research & Development expenses have been 3.19% of Revenue.
  • The Interest Expense is -7.60% of Operating Income.
  • The Net Earning history of PRPH is -37.81% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 15 years.

ProPhase Labs Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: PRPH
CUSIP: 74345W
Website: prophaselabs.com

Debt

Debt-to-Equity Ratio: 0.45
Current Ratio: 1.47
Quick Ratio: 1.12

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PRPH Technical Analysis vs Fundamental Analysis

Sell
18
ProPhase Labs (PRPH) is a Sell

Is ProPhase Labs a Buy or a Sell?

  • ProPhase Labs stock is rated a Sell
    The current ProPhase Labs [PRPH] share price is $0.77. The Score for PRPH is 18, which is 64% below its historic median score of 50, and infers higher risk than normal.